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Abstract
Background: Compared to healthy controls, people with Alzheimer’s disease (AD) have been shown to receive less
pain medication and report pain less frequently. It is unknown if these findings reflect less perceived pain in AD, an
inability to recognize pain, or an inability to communicate pain.
Methods: To further examine aspects of pain processing in AD, we conducted a cross-sectional study of sex-matched
adults ≥65 years old with and without AD (AD: n = 40, female = 20, median age = 75; control: n = 40, female = 20,
median age = 70) to compare the psychophysical response to contact-evoked perceptual heat thresholds of warmth,
mild pain, and moderate pain, and self-reported unpleasantness for each percept.
Results: When compared to controls, participants with AD required higher temperatures to report sensing warmth
(Cohen’s d = 0.64, p = 0.002), mild pain (Cohen’s d = 0.51, p = 0.016), and moderate pain (Cohen’s d = 0.45, p = 0.043).
Conversely, there were no significant between-group differences in unpleasantness ratings (p > 0.05).
Conclusions: The between-group findings demonstrate that when compared to controls, people with AD are less
sensitive to the detection of thermal pain but do not differ in affective response to the unpleasant aspects of thermal
pain. These findings suggest that people with AD may experience greater levels of pain and potentially greater levels
of tissue or organ damage prior to identifying and reporting injury. This finding may help to explain the decreased
frequency of pain reports and consequently a lower administration of analgesics in AD.
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Background
Poorly managed pain in people with Alzheimer’s disease
(AD) is a significant public health concern. AD in gen-
eral is a risk factor for the under-treatment of pain, due
in part to a lack of understanding of the impact of AD
on psychophysiological factors that influence the pain
experience. In the presence of similar painful conditions,
when compared to cognitively intact older adults, people
with AD have been shown to receive less pain medication
[1–3]. However, a recent large-scale study found that
when compared to people without dementia, people with
dementia reported pain less frequently and although they
reportedly used acetaminophen more frequently, there
were no significant differences in the use of opioids and
NSAIDs [4]. Furthermore, in the presence of similar pain-
ful conditions, people with AD verbally report pain less
frequently [5, 6] but exhibit similar pain-related behaviors
when moved [6]. It is unknown if these findings reflect less
* Correspondence: todd.b.monroe@vanderbilt.edu
1Vanderbilt University School of Nursing, Vanderbilt University Institute of
Imaging Science, Vanderbilt Psychiatric Neuroimaging Program, Nashville,
Tennessee, USA
Full list of author information is available at the end of the article
© 2016 Monroe et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Monroe et al. BMC Medicine  (2016) 14:74 
DOI 10.1186/s12916-016-0619-1
perceived pain in AD or an inability to recognize pain or
to communicate pain.
Nociceptive studies of pain examine underlying neuro-
physiological processes that may lead to the perception
of pain [7] whereas psychophysical studies examine self-
reports of pain perception [8]. This paper will examine
the latter. Pain is described as a multidimensional ex-
perience consisting of sensory, cognitive, and affective
components [9]. If one or more of these components is
altered in AD, the ability to detect and report pain may
also be altered. Findings from acute experimental pain
studies in AD are mixed. In response to contact heat
stimuli [10, 11], experimental electrical shock [12, 13],
mechanical pressure [14], CO2 laser [15], and ischemia
[16], the self-reported pain threshold does not differ be-
tween healthy controls and people with AD. However,
the magnitude of stimulus intensity required to reach
tolerance (stimulus reported as “unbearable”) was signifi-
cantly higher in AD, with pain tolerance increasing as AD
severity worsened [16]. Conversely, for suprathreshold
heat pain stimuli, people with AD reported more pain
(increased sensitivity) when compared to controls [11].
Relative to controls, people with AD demonstrated a
blunted autonomic response yet normal pain percep-
tion to a painful stimulus just above the pain threshold;
however, when the pain stimulus was increased to twice
the threshold, people with AD demonstrated a blunted
perceptual response to pain (but no difference in auto-
nomic response) [10]. These findings suggest that people
with AD have a variable pain response that is threshold
dependent [12]. Gibson and colleagues found that when
compared to controls, individuals with AD demonstrated
increased detection thresholds for just-noticeable sensa-
tion but the groups did not differ in their intensity ratings
in response to fixed temperatures [15]. Cole and col-
leagues found that compared to healthy controls, people
with AD displayed increased mechanical pressure pain
thresholds (i.e., decreased sensory sensitivity) for just-
noticeable pain and weak pain while also reporting
just-noticeable pain as more unpleasant [17].
As an alternative to examining verbal reports of pain,
some laboratories are examining facial affective responses
to pain, demonstrating that facial coding can effectively be
used to measure affective responses to evoked pain (pre-
sumably corresponding to pain unpleasantness) in people
with AD [18]. Kunz and colleagues observed that, relative
to controls, people with dementia demonstrated increased
facial pain affect to both mechanical pressure and electrical
shock [5, 14]. Similarly, Beach and colleagues recently
found that in response to pressure algometry, people with
AD demonstrated increased facial pain affect when com-
pared to controls [19].
In summary, these experimental pain studies suggest that
AD is variously associated with increased pain threshold
and tolerance with diminished sensitivity, no differences
relative to healthy individuals, or even increased pain un-
pleasantness. Reconciling these variations across studies is
difficult, but possible reasons include the use of different
experimental pain stimuli, different measures of psycho-
physics, varying degrees of cognitive impairment, and lim-
ited sample sizes.
Though the above-mentioned studies have provided
important insight into our understanding of pain process-
ing in dementia, no consensus has yet been reached regard-
ing the impact of AD on the experience of pain. Reasons
for this lack of consensus include the following: (1) measur-
ing stimulus intensity threshold verses pain tolerance, (2)
few studies have examined both threshold intensity and
self-report of pain, (3) few studies have examined supra-
threshold intensities, and (4) few studies have examined
suprathreshold stimuli which may be more relevant to clin-
ical pain when compared to pain threshold. Nonetheless,
there are efforts being made to reconcile this literature. A
recent review of responses to experimental pain stimuli
found that people with cognitive impairment generally ex-
hibit hypersensitivity rather than hyposensitivity to pain
[20]. Despite these efforts, key clinical questions remain un-
answered. The most important is whether decreased treat-
ment of pain in AD results from a decreased ability to
recognize and report pain, or whether AD-related changes
in pain systems result in altered pain perception relative to
healthy individuals. Such questions must be addressed to
help inform future research endeavors that seek to develop
evidence-based pain management in AD.
The purpose of this cross-sectional study was to compare
the psychophysical response to experimental thermal pain
in a group of older adults with AD to comparable individ-
uals without AD. To our knowledge, this is the first study
to use experimental thermal stimuli to assess pain percep-
tion at suprathreshold levels in conjunction with verbal re-
ports of unpleasantness in people diagnosed with mild to
moderate cognitive impairment in AD. Our first hypothesis
was that, when compared to sex and age-matched cogni-
tively intact controls, people with AD would be less sensi-
tive to thermal pain and find pain to be less unpleasant.
Our second hypothesis was that, among people with AD, a
surrogate index of greater AD severity, namely an increas-
ing global cognitive impairment as measured by the Fol-
stein Mini-Mental State Examination (MMSE) [21], would
be associated with higher thresholds for detecting thermal
stimuli (at warmth, mild pain, and moderate pain inten-
sities) and lower reported unpleasantness associated with
each of these intensities.
Methods
Participants
From a sample of 97 people ≥65 years old completing a lar-
ger study of mechanisms underlying AD-related alterations
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in pain responsiveness, 40 older adults with AD were
matched to 40 older adults without AD. The samples had
equal sex distributions (female = 20, male = 20) and very
similar age distributions (control: median = 70 years; AD:
median = 75 years). Four research assistants enrolled the
participants included in the current study over a 3-year
period from 2012 to 2015. Participants with a clinical
diagnosis of AD were recruited from the practices of
three geriatricians, two geriatric psychiatrists, and a
neurologist from Vanderbilt University Medical Center.
Medical records were reviewed to confirm the presence
of an AD diagnosis based on supportive documentation
including the following: (1) neuropsychiatric evaluation,
diagnostic MRI or PET, and/or serum laboratory tests
eliminating other potential causes of memory loss (e.g.,
vitamin B12, thyroid hormone, complete blood count,
electrolyte balance, HIV), and (2) clinical diagnostic
support based on results on evaluation with the MMSE
[21], the Montreal Cognitive Assessment (MoCA) [22],
and/or the Functional Assessment Staging (FAST) Scale
[23]. Although not all measures necessary to evaluate
the criteria were consistently available in the medical
records, approximately 62 % of patients met the Na-
tional Institute of Neurological and Communicative
Disorders and Stroke and the Disease and Related Dis-
orders Association (NINCDS-ADRDA) [24] criteria for
AD. The extent of global cognitive impairment in people
with AD was assessed with the MMSE. To be included,
all participants with AD were required to be verbally
communicative and able to provide a verbal pain rating.
Controls were recruited from Vanderbilt University’s
Research Match Trial Registry and via advertising
through posted flyers from the greater Nashville, TN,
USA, metropolitan area.
To reduce potential confounds to testing study hy-
potheses and for safety reasons, potential participants
were excluded for regular use of opioid or non-opioid
pain medications, history of stroke, cancer, peripheral
neuropathy, unstable cardiac conditions, unstable respira-
tory conditions, insulin-dependent diabetes, psychiatric dis-
orders (e.g., schizophrenia, bipolar disorder, depression),
current or recent substance use disorders, or Parkinson’s
disease. Using these exclusion criteria resulted in a physio-
logically healthy group of people clinically diagnosed with
AD. With their legal surrogate present when appropriate
(i.e., for individuals with AD), participants were instructed
to avoid taking any pain medication (opioid or non-opioid)
for at least 24 hours prior to data collection. The current
study was approved by the Vanderbilt University Institu-
tional Review Board. Prior to enrollment, each participant
provided written informed consent. In individuals lacking
decisional capacity, participant assent and legal surrogate
consent were obtained. Participants and their caregivers
were each reimbursed US$100 for their time.
Procedures
Measures
Prior to the collection of any questionnaire data and pain
psychophysics, participants (and their legal caregiver when
present) were presented with an opportunity to experience
the thermal pain stimulus and to complete two practice
psychophysics trials. Practice trials were completed
prior to psychophysical testing to ensure participants
understood the directions and that their responses were
appropriate (e.g., that warmth detection occurred at a
lower temperature than mild pain detection, which oc-
curred at a lower temperature than moderate pain
detection).
All study measures were collected at the participant’s
residence or Vanderbilt University Medical Center. After
meeting the initial screening requirements above, and
before continuing with enrollment, each participant’s
capacity to consent was assessed using the University of
California San Diego Brief Assessment of Capacity to
Consent (UBACC) [25]. This form takes less than 5 minutes
to complete, with scores >14.5 being 89 % sensitive and
100 % specific for determining capacity to consent for re-
search [25]. Participants with scores >14.5 on the UBACC
were permitted to sign the informed consent document; in-
dividuals with scores ≤14.5 were permitted to sign the
assent document and legal surrogate consent was obtained.
After obtaining consent, participants underwent 1 hour
of demographic and psychosocial assessments. Because
the current study included communicative people with
mild to moderate cognitive impairment in AD, a trained
research assistant administered all demographic and data
questionnaires orally to all participants. These included
a detailed list of all medications and the Hollingshead
Four-Factor Index of Socioeconomic Status (SES) [26].
The Brief Pain Inventory Short Form (BPI-SF) was used
to collect current clinical pain and average daily pain
[27]. Depression and anxiety screens included the Geri-
atric Depression Scale Short Form (GDS-SF) [28] and
the state and trait forms of the Spielberger State-Trait
Anxiety Inventory [29], respectively.
Psychophysical thermal stimulation protocol
The psychophysical testing procedures used in this study
have been previously described in detail [30]. In brief,
responses to thermal stimuli were assessed with the
Medoc Q-Sense (Medoc Ltd., Rimat Yishai, Israel) or
the Medoc fMRI-compatible ATS-CHEPS Model Pain
and Sensory Evaluation System (Medoc Ltd.) [31]. Both
systems were calibrated and set to deliver a stimulus in-
tensity beginning at a baseline of 30 °C with an upward
ramp rate of 1 °C/s using a 30 mm× 30 mm thermode
placed on the thenar eminence of the right hand. We modi-
fied the stimulus intensity matching the protocol used by
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Cole and colleagues in their successful psychophysical study
of mechanical pressure pain in people with AD [17]. Before
beginning, it was explained to participants that there
were two qualities of pain they would be asked to re-
port: the intensity, that is “how strong the pain feels,”
and the unpleasantness, “how unpleasant or disturbing
the pain is for you” [32]. Next the Method of Limits
program was used to deliver a thermal stimulus. Partic-
ipants were instructed to press a button to stop the
heat stimulus when they perceived (in separate trials)
the sensations of warmth, mild pain, and moderate
pain. Participants were then told, “After you stop the
heat, I will ask you to tell me how unpleasant the previous
temperature was.” To assess unpleasantness, participants
were then shown a 0–20 unpleasantness scale (0 = neutral,
20 = very intolerable) that has been successfully used in
research in older adults with AD [17, 33–35]. Thermal
paradigm instructions were repeated before each ther-
mal stimulus delivery and then the instructions for rat-
ing unpleasantness were repeated after each stimulus
delivery. After completing practice trials, three trials of
each of the three stimulus conditions and associated
unpleasantness ratings were conducted, and the average
temperature and unpleasantness rating for each percept
(warmth, mild pain, and moderate pain) were recorded.
Data analysis
There were no missing values for the critical study vari-
ables (AD diagnosis, sex, age, BPI-SF scores). Missing data
for the other demographic and sample descriptor variables
were random in nature. The continuous demographic,
standardized measures, and psychophysical values were
summarized using median and inter-quartile range (IQR)
due to lack of normality (Fisher test > ±2.58, p < 0.01).
Categorical data were summarized using frequency dis-
tributions. Comparisons between the AD group and the
control group were conducted using nonparametric
Mann–Whitney tests (continuous and ordinal data)
and chi-square tests (categorical data). Generalized lin-
ear modeling using the log link function was used to
test for main and interaction effects of AD and sensory
level (i.e., warmth, mild pain, or moderate pain) inten-
sity on the temperatures and ratings of unpleasantness.
Cohen’s d effect size indices were generated to summarize
the magnitude of the AD effects. Linear regressions within
each sensory level using rank-transformed data were used
to assess the associations of the severity of global cognitive
impairment (MMSE scores) with temperature thresholds
and unpleasantness ratings. Due to the known associations
of depression with perceptions of pain intensity, the pri-
mary analyses were repeated with GDS-SF scores included




Statistically significant differences between the AD and
control groups were observed for SES, which were due
to differences in education level (p = 0.044). Participants
in the control group tended to be more highly educated
than those in the group with AD. No other statistically
significant demographic differences were observed other
than for the two variables known to be associated with
cognitive decline (MMSE and GDS-SF depressive symp-
toms, both p < 0.001; see Table 1).
Psychophysical results
Between-groups effects
A statistically significant main effect of AD group versus
control was observed for the stimulus intensity required
to evoke the three targeted sensory descriptors (Wald
chi-square (df = 1) = 7.71, p = 0.005). Pairwise comparisons
indicated that participants with AD required higher tem-
peratures to report sensing “warmth” (Cohen’s d = 0.64,
p = 0.002), “mild pain” (Cohen’s d = 0.51, p = 0.016), and
“moderate pain” (Cohen’s d = 0.45, p = 0.043; see Table 2).
There were no statistically significant differences between
the groups in ratings of unpleasantness at any stimulus
intensity (Wald chi-square (df = 1) = 0.05, Cohen’s d =
0.04–0.18, p = 0.823; see Table 2). Similar findings for
both temperature and unpleasantness were observed from
additional analyses that controlled for GDS-SF (depressive
symptom) scores.
Effects of severity of global cognitive impairment
Hypotheses regarding effects of worsening global cogni-
tive impairment on pain responses were tested within
the AD group alone (because there was minimal vari-
ation in MMSE in the control group). Results revealed
that worsening global cognitive ability was associated
with higher temperatures required to report “warmth”
(beta = −0.37, Cohen’s d = 0.80, p = 0.020), yet not “mild
pain” (beta = 0.01, Cohen’s d = 0.02, p = 0.966) or “mod-
erate pain” (beta = 0.01, Cohen’s d = 0.02, p = 0.942) (Fig.
1). Within the AD group, temperatures required to reach
each target percept and pain unpleasantness values were
not meaningfully associated with depressive symptoms
(r = 0.06–0.22, p > 0.20). Thus, analyses controlling for
depressive symptoms did not modify the reported find-
ings. Consistent with the between-groups analyses, no
statistically significant associations of worsening global
cognitive function were observed with ratings of un-
pleasantness within the AD group: warmth: beta = −0.22,
Cohen’s d = 0.45, p = 0.167; mild pain: beta = −0.20,
Cohen’s d = 0.41, p = 0.221; moderate pain: beta = −0.21,
Cohen’s d = 0.43, p = 0.192 (Fig. 2).
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Discussion
This study compared the perception threshold for three
experimental heat pain intensities and reports of un-
pleasantness associated with each of the three percepts
in a sex and age-matched sample of older adults with
and without mild to moderate cognitive impairment in
AD. Our first hypothesis, that people with AD would be
less sensitive to thermal pain and find pain to be less
unpleasant than would cognitively intact controls, was
partially supported. Compared to healthy controls, people
diagnosed with AD were less pain sensitive: they demon-
strated higher intensity thresholds for the detection of
“warmth,” “mild pain,” and “moderate pain.” However, des-
pite requiring higher stimulus temperatures to reach these
three perceptual thresholds, people with AD reported simi-
lar levels of pain-associated unpleasantness across the three
percepts when compared to controls. Our second hypoth-
esis, that as global cognitive function worsens, people with
Table 1 Demographic and clinical summaries by Alzheimer’s diagnosis
Total (N = 80) Control (N = 40) AD (N = 40) p-value
N (%) N (%) N (%)
Gender 1.000
Female 40 (50.0) 20 (50.0) 20 (50.0)
Male 40 (50.0) 20 (50.0) 20 (50.0)
Race N = 79 n = 39 n = 40 0.818
African American 10 (12.7) 4 (10.3) 6 (15.0)
Asian 2 (2.5) 1 (2.6) 1 (2.5)
Caucasian 67 (84.8) 34 (87.2) 33 (82.5)
Education N = 77 n = 38 n = 39 0.044
High school or less 14 (18.2) 5 (13.2) 9 (23.1)
Partial college 20 (26.0) 11 (28.9) 9 (23.1)
College graduate 22 (28.6) 7 (18.4) 15 (38.5)
Graduate school 21 (27.3) 15 (39.5) 6 (15.4)
Marital status N = 78 n = 39 n = 39 0.845
Single/divorced/separated 16 (20.5) 9 (23.1) 7 (17.9)
Married 46 (59.0) 22 (56.4) 24 (61.5)
Widowed 16 (20.5) 8 (20.5) 8 (20.5)
Marriage occupation status N = 77 n = 39 n = 38 0.736
One spouse employed 40 (51.9) 21 (53.8) 19 (50.0)
Both employed 37 (48.1) 18 (46.2) 19 (50.0)
N, median [IQR] N, median [IQR] N, median [IQR]
Spouse’s occupation score 78, 3.5 [0–7] 39, 3.0 [0–8] 39, 4.0 [0–7] 0.567
Age 80, 73.0 [68–80] 40, 70.0 [66–81] 40, 75.0 [71–79] 0.089
Standardized measures
Body mass index 77, 25.5 [23–29] 40, 25.5 [23–29] 37, 25.1 [22–28] 0.269
Total SES scorea 77, 55.0 [19–30] 39, 57.0 [45–64] 38, 50.0 [39–56] 0.046
MMSE scoreb 79, 27.0 [19–30] 39, 30.0 [29–30] 40, 19.5 [14–24] <0.001
BPI-SF average painc 80, 0.0 [0–2] 40, 1.0 [0–2] 40, 0.0 [0–2] 0.059
BPI-SF pain right nowc 80, 0.0 [0–0] 40, 0.0 [0–1] 40, 0.0 [0–0] 0.203
GDS-SF scored 78, 1.0 [0–4] 40, 0.0 [0–2] 38, 3.0 [1–5] <0.001
STAI state scoree 68, 47.0 [44–50] 38, 47.0 [44–50] 30, 47.0 [43–50] 0.813
STAI trait scoree 68, 48.0 [45–51] 38, 48.5 [45–53] 30, 47.0 [44–51] 0.230
aSES Hollingshead Four Factor Index of Socioeconomic Status (range = 8–66; 8 = lowest, 66 = highest)
bMMSE Folstein Mini Mental State Examination (range = 0–30; 0 = completely cognitively impaired, 30 = completely cognitively intact)
cBPI-SF Brief Pain Inventory Short Form (range = 0–10; 0 = no pain, 10 =most pain)
dGDS-SF Geriatric Depression Scale Short Form (range = 0–15; 0 = no indication of depression, 15 = high possibility of depression)
eSTAI Spielberger State or Trait Anxiety Inventory (range 20–80; 20 = indicates increased anxiety, 80 = indicates least amount of anxiety)
AD Alzheimer’s disease, IQR interquartile range
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AD would become less sensitive to pain and find pain less
unpleasant, was not supported.
Our findings are in agreement with several previous
studies. Cole and colleagues [17] found that, compared
to controls, people with AD demonstrated higher mech-
anical pressure pain thresholds (less sensitivity) for just-
noticeable pain and weak pain. Similarly, Gibson and
colleagues [15] found that, compared to controls, people
with AD demonstrated increased detection thresholds
for pain sensation.
Unlike many previous studies, the current study also
examined self-reports of unpleasantness ratings associated
with each perceptual threshold examined (“warmth,” “mild
pain,” and “moderate pain”) and found no differences in
unpleasantness ratings between controls and participants
with AD. Finding no differences in self-reported pain
unpleasantness between controls and people with AD ini-
tially seems to be in contrast to work demonstrating in-
creased facial affective pain responses in AD [5, 14, 19].
Although reasons cannot be conclusively determined,
Table 2 Psychophysical summary of temperature thresholds necessary to produce ratings at each condition in a sex-age matched
sample of people with and without Alzheimer’s disease
Total (N = 80) Control (N = 40) AD (N = 40) p-value Cohen’s d
Median [IQR] Median [IQR] Median [IQR]
Just-noticeable warmth
Temperature 33.0 [32–35] 32.0 [32–34] 34.0 [33–36] 0.002 0.64
Affect 0.0 [0–2] 0.0 [0–2] 0.0 [0–1] 0.846 0.04
Weak pain
Temperature 37.0 [35–41] 35.5 [34–39] 39.0 [35–42] 0.016 0.51
Affect 4.0 [0–5] 3.3 [0–5] 4.0 [1–6] 0.402 0.18
Moderate pain
Temperature 42.0 [38–45] 40.0 [38–44] 43.0 [39–45] 0.043 0.45
Affect 6.0 [5–8] 6.0 [5–8] 6.5 [4–9] 0.867 0.04
Temperature was measured in degrees Celsius (range = 30–55 °C). Affect is the affective distress measured via a 0–20 Unpleasantness scale (0 = neutral,
20 = extremely unpleasant). The p-value was derived from a Mann–Whitney U Test. AD Alzheimer’s disease, IQR interquartile range
Fig. 1 Within the Alzheimer’s disease (AD) group only, association of temperature sensation for the detection of “warmth,” “mild pain,” and
“moderate pain” in degrees Celsius (range = 30–55 degrees Celsius) and global cognitive impairment in AD (Mini-Mental State Examination
[MMSE] score; range 0 = completely cognitively impaired to 30 = completely cognitively intact)
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these differences across studies may relate to the psycho-
physical methods used in the current study (the stimulus
intensity of each percept level was individually adjusted
for each individual rather than using a fixed intensity) or
in the measures used to assess the affective response to
pain (self-report ratings versus observed facial affect).
Interestingly, when examining the association between
global cognitive function and pain responses, the current
study found no evidence to suggest that worsening glo-
bal cognitive function was associated with lower reports
of unpleasantness in the presence of mild and moderate
pain. This finding does not appear to support a long-
standing hypothesis that the affective/motivational com-
ponent of pain may be altered in AD [36]. The current
findings appear somewhat divergent with findings of
Benedetti and colleagues [16], who reported that toler-
ance to highly unpleasant evoked pain stimuli (electrical
shock and ischemic arm pain) was increased in people
with worsening AD. Furthermore, Scherder and colleagues
[37] found that, compared with controls, people with
AD reported lower pain intensity and pain affect on re-
peated daily pain assessments. Similarly, an earlier study by
Scherder and colleagues [38] found that, after matching for
painful conditions and despite receiving similar amounts of
analgesics, people with AD reported lower pain intensity
and pain affect than non-AD controls [38]. In addition to
using a perceptually matched psychophysics paradigm in
the current study, a likely reason for differences in
unpleasantness ratings between previous and current study
findings is that Scherder and colleagues [38] used a 5-item
number of chosen words-affective scale [39] versus a 0–20
unpleasantness scale such as that used in the current study.
Taken together with previous work, findings from the
current study continue to demonstrate that, when com-
pared to healthy individuals, people with AD seem to have
altered detection levels for painful stimuli. The current
findings seem to support an emerging pattern in the litera-
ture demonstrating that detection thresholds for lower, less
noxious, levels of pain may be elevated in individuals with
AD compared to those without AD. In contrast, although
the current study found increased thresholds for detecting
moderate pain in people with AD as a group compared to
non-AD controls, there did not appear to be any influence
of worsening global cognitive impairment on detection
threshold for moderate pain (effect sizes were near zero).
Thus, current findings partially support and extend previ-
ous work by Scherder and colleagues [37], demonstrating
that people with AD may be less sensitive to pain than
healthy controls. However, we found no evidence using
controlled evoked pain stimuli to corroborate their findings
that clinical pain becomes less unpleasant as AD severity
worsens.
The clinical implications of altered reporting of pain in
AD patients may include increased risk of late or failed
detection of an underlying pathology requiring immedi-
ate attention. Diminished ability to detect pain could
Fig. 2 Within the Alzheimer’s disease (AD) group only, association of unpleasantness ratings (range 0 = neutral to 20 = extremely
intolerable) for “warmth,” “mild pain,” and “moderate pain” and global cognitive impairment in AD (Mini-Mental State Examination
[MMSE] score; range 0 = completely cognitively impaired to 30 = completely cognitively intact)
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lead to increased negative outcomes once pain is rec-
ognized. For example, Morrison and colleagues found
that when assessing post-operative hip pain, people
with AD reported increased levels of pain, increased
length of hospitalization, and decreased ability to ambulate
3 months post-operatively [3].
There are some limitations in the current study that
should be considered when interpreting results. People
with an existing clinical diagnosis of AD from several
different clinician practices were included and thus no
single AD diagnostic procedure was selected. We realize
that other sensory modalities (e.g., somatosensory, audi-
tory) may have contributed to the overall pain experience;
however, we believe the current study design examining
pain psychophysics helps to address a clinically relevant
problem, altered pain processing in AD. Interestingly, we
did not find an association between perceptual pain thresh-
olds and depression in the AD group. We believe, however,
it is possible that the limited variability of GDS-SF scores
within the AD group contributed to the failure to uncover
an association between depression and pain. A perceptual
matching paradigm was used for thermal sensory detection
levels. Because of this, individual ratings of unpleasantness
were based on perceptually matched thresholds for
warmth, mild pain, and moderate pain and not on a fixed
temperature paradigm. This procedure may have impacted
on the pattern of findings for pain unpleasantness in un-
known ways. Despite these limitations the current study
adds to the limited number of clinical and experimental
pain studies examining altered pain response in AD.
Distinguishing between pain intensity and pain affect
in both the acute and chronic pain context is critical to the
translational relevance of future pain studies in dementia.
Although the literature continues to demonstrate mixed
results, it is becoming increasingly clear that, relative
to non-AD controls, people with AD generally have an
altered response to clinical and experimental pain. It
has been suggested that clinicians consider using both
intensity and affective (qualitative) scales when assessing
pain in AD [38]. Moreover, as recently demonstrated by
several laboratories [5, 14, 19], assessing nonverbal
emotion-related measures such as facial affect during
acutely painful experiences (e.g., bathing, turning, trauma,
post-operative procedures) may be particularly useful in
the AD population.
Conclusions
Findings from the current study support the idea that
the “pain threshold” may have less relevance to clinical
pain states, and that “suprathreshold” pain responses
need to be examined in a systematic fashion. Moving
forward, it is critical to increase our understanding of
the psychophysical response to pain in dementia, yet in
order to complement this important work, we urgently
need to increase our understanding of the underlying
neurophysiological alterations contributing to pain alter-
ations in dementia. As people age, the risk of developing
pain increases and as the population of older adults con-
tinues to grow, so will the number of people diagnosed
with dementia who have pain. Finding ways to improve
pain care in people with all forms of dementia is crucial
to alleviate unnecessary suffering in this highly vulnerable
population.
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